Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate-specific antigen.

U H Stenman1, J Leinonen, W M Zhang

  • 1Department of Clinical Chemistry, Helsinki University Central Hospital, Helsinki, FIN-00290, Finland.

Seminars in Cancer Biology
|April 15, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unveiling Challenges Hindering the Growth of Home Dialysis in Finland: Insights From 40 Years of Experience.

Hemodialysis international. International Symposium on Home Hemodialysis·2025
Same author

Altered acylcarnitine metabolism and inflexible mitochondrial fuel utilization characterize the loss of neonatal myocardial regeneration capacity.

Experimental & molecular medicine·2023
Same author

Mortality due to bleeding, myocardial infarction and stroke in dialysis patients.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Mortality due to pulmonary embolism, myocardial infarction, and stroke among incident dialysis patients.

Journal of thrombosis and haemostasis : JTH·2012
Same author

Stability of first trimester placental growth factor in serum and whole blood.

Prenatal diagnosis·2011
Same author

Decline in the incidence of renal failure due to amyloidosis associated with inflammatory rheumatic diseases.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis·2011

Prostate specific antigen (PSA) is a sensitive marker for prostate cancer, but benign prostatic hyperplasia (BPH) often causes false positives. Measuring free PSA improves cancer specificity, especially in the diagnostic grey zone.

Area of Science:

  • Biochemistry
  • Oncology
  • Urology

Background:

  • Prostate specific antigen (PSA) is a serine protease crucial for seminal fluid liquefaction.
  • Elevated serum PSA levels are indicative of prostate disease, including cancer and benign prostatic hyperplasia (BPH).
  • PSA's utility as a prostate cancer marker is limited by BPH-related false positives, particularly in men over 50.

Purpose of the Study:

  • To evaluate the diagnostic utility of PSA and its complexes in distinguishing prostate cancer from BPH.
  • To explore the role of free PSA and PSA-alpha1-antichymotrypsin (PSA-ACT) complexes in improving diagnostic accuracy.
  • To assess the potential of statistical methods and combined markers for enhanced prostate cancer detection.

Main Methods:

  • Analysis of PSA and its complexes (PSA-ACT, free PSA) in serum samples.

Related Experiment Videos

  • Comparison of marker proportions between prostate cancer and BPH patient groups.
  • Application of statistical models, including logistic regression and neural networks, for diagnostic accuracy improvement.

    • Main Results:

    • The proportion of PSA-ACT complexes is higher, and free PSA is lower in prostate cancer compared to BPH.
    • Free PSA determination significantly enhances the specificity of PSA testing, particularly in the 4-10 microg/l range.
    • Combined analysis of PSA, its complexes, and clinical data (DRE, TRUS, heredity) improves diagnostic performance.

    Conclusions:

    • Free PSA measurement is valuable for improving prostate cancer specificity, especially in the diagnostic grey zone.
    • Further improvements in prostate cancer diagnosis can be achieved by analyzing PSA in conjunction with other protease inhibitors and clinical factors.
    • Statistical modeling offers a robust approach to integrate multiple markers and clinical findings for more accurate prostate cancer detection.